PDF Presentations
Please click on the hyperlinked title to open the slide presentation in PDF format of the conference speaker. Each Speaker name is also hyperlinked with their short Bio.
Poster Abstracts are available at the end of the program.
Pre-conference Workshop-2011: DDI Data Evaluation - Chair: Walt Woltosz
Opening Remarks- Albert P. Li
Use of Physiologically Based Pharmacokinetic Modeling for Assessment of Drug-Drug Interaction Potential in Early Development Projects (Neil Parrot, F. Hoffmann-La Roche Ltd., Basel, Switzerland)
Turning up the Power: Predicting the Extent of Enzyme Induction (Geoffrey Tucker, University of Sheffield/SimCYP Ltd, Sheffield, UK)
Analysis of Transporter Mediated Drug-Drug Interaction in the Kidney and Brain (Yuichi Sugiyama, University of Tokyo; Tokyo, Japan)
Other Mechanisms for Drug-Drug Interactions (Walt Woltosz, Simulations Plus, Inc.; Lancaster, CA)
Main Conference: 14th International Conference on Drug-Drug Interactions: Session I: Preclinical and Clinical Review - Chair: Ken Thummel
Opening Remarks & Overview: Current Status of DDI (Ken Thummel, University of Washington; Seattle, WA)
Critical Review of the Literature 2010-2011 (Sophie Chung/Isabelle R Majlessi, University of Washington; Seattle, WA)
Clinical DDI Update: New Molecular Entities Approved by FDA in 2010 (Carol Collins, University of Washington; Seattle, WA)
Session II: Novel DDI Concepts and Approaches - Chair:
Can Lysosomal Trapping Cause Drug-Drug Interaction? (Mingxiang Liao, Millennium: The Takeda Oncology Company; Cambridge, MA)
Contribution of Metabolites to Drug-Drug Interaction (Viera Lukacova, Simulations Plus, Inc.; Lancaster, CA)
CYP 2J2: Substrates, Inhibitors and Inducers (Rheem Totah, University of Washington; Seattle, WA)
In Vitro Evaluation of Intestinal MDR1 Induction (N.L. Simmons, University of Newcastle upon Tyne; Tyne and Wear, UK)
Session III: Enzyme Inhibition - Chair: Ken Grime
Key Challenges for the Prediction of Clinical Drug-Drug Interactions with Pre-Clinical Data (Geoffrey Tucker, SimCYP Ltd; Sheffield, UK)
Selection of P450 Substrates on the Accuracy of In Vitro Prediction of In Vivo Drug Interactions (Rob Foti, Amgen, Inc.; Thousand Oaks, CA)
Mechanism-based Inhibition of Cytochrome P450 Enzymes: An Evaluation of Early Decision Making In Vitro Approaches and Drug–Drug Interaction Prediction Methods (Ken Grime, AstraZeneca R&D Charnwood; Loughborough, UK)
Uncomplicating Time-dependent Cytochrome P450 Inhibition Assays: Considerations for the Preincubation Step, Data Processing and Application of the Dilution Method in Abbreviated Testing (David Stresser, BD Biosciences; Woburn, MA)
Prediction of Drug-Drug Interactions as a Result of CYP3A Reversible and Time-Dependent Inhibition Using Human Hepatocytes Suspended in Human Plasma (Jialin Mao1,*, Michael A. Mohutsky1, John P. Harrelson2, Steven A. Wrighton1 and Stephen D. Hall1:1 Lilly Research Labs, Eli Lilly and Co., Indianapolis, IN; 2 Pacific University, Hillsboro, OR; * Current Affiliation: Pfizer, La Jolla, CA)
Analysis of the Pharmacokinetic Boosting Effects of Ritonavir on Oral Bioavailability of Drugs (Mariko Morishita, Hoshi University, Tokyo, Japan)
Threshold for Metabolites to Trigger In Vitro DDI Studies: Consideration of Abundance and Inhibition Potency BIO:(Hongbin Yu, Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT)
Session IV: Enzyme Induction - Chair: Sharon Ripp
Assessing In Vitro and In Vivo Induction of Cytochrome P450: Perspectives from PhRMA (Sharon Ripp, Pfizer Global Research & Development; Groton, CT)
Induction of UDP-Glucuronosyltransferase (UGT) Enzymes (Brian Ogilvie, LLC; Lenexa, KS)
Session V: Transporter-Related DDI - Chair: Kenneth Brouwer
Predictions of Transporter-mediated Drug-Drug Interactions in the Liver from In Vitro Data (Yuichi Sugiyama, University of Tokyo; Tokyo, Japan)
Hepatic Uptake Transporters and their Role for Drug-Drug Interactions (Jörg König, Institute of Experimental and Clinical Pharmacology and Toxicology; Erlangen, Germany)
Modulators of MRP2 Activities: Species Differences and In Vitro-In Vivo correlation (Krisztina Herédi-Szabó, SOLVO Biotechnology; Szeged, Hungary)
In Vitro Models for the Evaluation of Uptake and Efflux Transporters: Considering Background Contributions (Mark Warren, Optivia Biotechnology, Inc.; Menlo Park, CA)
Species Comparison of Efflux Transporter-related Drug-Drug Interactions (Kenneth Brouwer, Qualyst, Inc.; Durham, NC)
In Vitro-In Vivo Correlation of Renal Transporter-mediated DDIs (Bo Feng, Pfizer Global Research & Development; Groton, CT)
Characterization of Transporters in Human Adult and Pediatric Hepatocytes (Lilly Xu, Amgen; Thousand Oaks, CA)
Session VI: DDI of Biologics - Chair: Eugenia Kraynov SESSION VI SPONSOR: PFIZER GLOBAL RESEARCH AND DEVELOPMENT
Current Industry Perspective on BioTx DDI (Honghui Zhou, Johnson & Johnson PRD; New Brunswick, NJ)
Current Scientific Learning about Drug-Drug Interactions Involving Biologics (Liang Zhao, U. S. FDA; Silver Spring, MD)
Use of Pre-clinical Animal Models for Evaluation of Biotherapeutics DDI (Eugenia Kraynov, Pfizer Global Research & Development; San Diego, CA)
In Vitro Methodologies to Evaluate the Potential for Drug-Drug Interactions between Therapeutic Proteins and Small Molecules (Theresa Nguyen, Merck & Co., Inc.; Rahway, NJ)
Effects of IL-6 on Transporter and P450 Gene Expression (Qian Yang, Doshi Utkarsh, Albert P. Li, APSciences, APSciences, Inc.; Columbia, MD)
End DDI-2011
ETS-2011: 9th International Conference on Early Toxicity Screening: Transporters and Drug Toxicity - June 9-10, 2011
Session I: Scientific Concepts of Transporters and Drug Interactions - Chair: Jash Unadkat
Keynote Presentation: Transporters on the Target Organs and Clearance Organs are Responsible for Drug Induced Toxicities (Yuichi Sugiyama, University of Tokyo; Tokyo, Japan)
The Role of Nucleoside Transporters in Drug Toxicity (Jash Unadkat, University of Washington; Seattle, WA)
Differences in Transporter-mediated Tissue Accumulation between Two Structurally Similar Antiparasitic Agents may Contribute to Differences in Toxicity Potential (Mary Paine, University of North Carolina at Chapel Hill; Chapel Hill, NC)
Session II: Clinical Evidence of Transporter-related Drug Toxicity - Chair: Christopher MacLauchlin
Clinical Efficacy and Toxicity of Lapatinib: Deciphering the Role of Transporters (Christopher Maclauchlin, GlaxoSmithKline; Research Triangle Park, NC)
SLCO1B1*5 Genetic Variant and Statin-Induced Myopathy (Deepak Voora, Duke University; Durham, NC)
HIV Protease Inhibitors and the Metabolic Syndrome: Role of Glucose Transport Inhibition (Oliver Flint, Bristol Myers Squibb; Princeton, NJ)
Efflux transporter Inhibition and Hepatotoxicity of HER2 Tyrosine Kinase Inhibitors (Bo Feng, Pfizer Global Research & Development; Groton, CT)
Session III: Experimental Approaches for Transporter-related Drug toxicity - Chair: Albert P. Li
Experimental Evaluation of Efflux Transporters-related Hepatotoxicity (Kenneth Brower, Qualyst; Durham, NC)
Transporters and Drug Toxicity during Drug Development (Xun Zhang, Pfizer Global Research & Development; Groton, CT)
Role of Transporters of Toxicity of Biologics (Loi Cho-Ming, Pfizer Global Research & Development; San Diego, CA)
Potential for Increased Risk of Adverse Drug Reactions due to Alterations in Transporter Function in Human and Experimental Fatty Liver Disease (Nathan Cherrington, University of Arizona; Tucson, AZ)
Approach to Predict OATP-mediated drug-drug interactions: Industry Case Studies (Xiaoyan Chu, Merck & Co., Inc.; Rahway, NJ)
Effects of inflammatory cytokines on transporter gene expression in human hepatocytes: implications in drug-induced liver toxicity (Albert P. Li, APSciences, Inc and In Vitro ADMET Labs; Columbia, MD)
Utilization of Calcein AM as P-gp Probe Substrate in Various In Vitro Assay Systems – A Correlation Study (Krisztina Herédi-Szabó, SOLVO Biotechnology; Szeged, Hungary)
Lysosomal Trapping of Lipophilic Amines and its Relationship to Drug Transporters and Phospholipidosis (Andrew Parkinson, XenoTech LLC; Lenexa, KS)
Recent Regulatory Updates for Transporter Mediated Drug Interaction Assessments to Ensure Patient Safety (David Lustig, Optivia Biotechnology; Menlo Park, CA)
Concluding Remarks: Albert P. Li, APSciences, IVAL; Columbia, MD
PLEASE VISIT US ONLINE AT IFSCOMM.ORG